5 Hos patienter med risiko for akut nyresvigt eller thromboemboliske uønskede reaktioner bør IVIg - produkter indgives med den minimalt anvendelige infusionshastighed og dosis.
In patients at risk for acute renal failure or thromboembolic adverse reactions, IVIg products should be administered at the minimum rate of infusion and dose practicable.